IL37 and inflammatory bowel disease: Because of the shared genetic and immunologic features of psoriasis and IBD, certain classes of biologic therapy are nowadays used to control flares for both diseases, especially TNF-alpha inhibitors, ustekinumab, and IL-23 inhibitors [26,30,31,32,33,34,35].